{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:21:38Z","timestamp":1762521698313},"reference-count":77,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council Australia","doi-asserted-by":"publisher","award":["440200","1007518"],"award-info":[{"award-number":["440200","1007518"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council Australia","doi-asserted-by":"publisher","award":["1007994"],"award-info":[{"award-number":["1007994"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.vaccine.2014.08.048","type":"journal-article","created":{"date-parts":[[2014,8,27]],"date-time":"2014-08-27T04:56:59Z","timestamp":1409115419000},"page":"34-51","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries"],"prefix":"10.1016","volume":"33","author":[{"given":"Leonardo","family":"Simonella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Canfell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"47","key":"10.1016\/j.vaccine.2014.08.048_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.15.47.19730-en","article-title":"The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey","volume":"15","author":"Dorleans","year":"2010","journal-title":"Euro Surveill"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.048_bib0010","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1071\/SH10001","article-title":"Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register: Australia","volume":"8","author":"Gertig","year":"2011","journal-title":"Sex Health"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.048_bib0015","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2165\/00019053-200927020-00004","article-title":"Effectiveness and cost effectiveness of human papillomavirus vaccine: a systematic review","volume":"27","author":"Marra","year":"2009","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.048_bib0020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/IGC.0b013e3181a130c0","article-title":"Epidemiological and economic impact of human papillomavirus vaccines","volume":"19","author":"Jeurissen","year":"2009","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.vaccine.2014.08.048_bib0025","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1586\/14760584.7.7.895","article-title":"Structural differences among cost-effectiveness models of human papillomavirus vaccines","volume":"7","author":"Insinga","year":"2008","journal-title":"Expert Rev Vaccines"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2014.08.048_bib0030","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1159\/000214924","article-title":"Economic evaluation of human papillomavirus vaccination in developed countries","volume":"12","author":"Brisson","year":"2009","journal-title":"Public Health Genomics"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.048_bib0035","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S1473-3099(07)70083-X","article-title":"Cost-effectiveness analyses of human papillomavirus vaccination","volume":"7","author":"Newall","year":"2007","journal-title":"Lancet Infect Dis"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2014.08.048_bib0040","doi-asserted-by":"crossref","first-page":"F3","DOI":"10.1016\/j.vaccine.2008.02.004","article-title":"Evolution of the health economics of cervical cancer vaccination","volume":"26","author":"Ferko","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0045","series-title":"Public health workshop. 28th International human papillomavirus conference & clinical and public health workshops","article-title":"Cost-effectiveness and impact studies of prevention of HPV-associated disease in higher income countries","author":"Canfell","year":"2012"},{"issue":"Suppl. 10","key":"10.1016\/j.vaccine.2014.08.048_bib0050","doi-asserted-by":"crossref","first-page":"K76","DOI":"10.1016\/j.vaccine.2008.06.009","article-title":"Modeling cervical cancer prevention in developed countries","volume":"26","author":"Kim","year":"2008","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2014.08.048_bib0055","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1071\/SH10018","article-title":"A brief history of economic evaluation for human papillomavirus vaccination policy","volume":"7","author":"Beutels","year":"2010","journal-title":"Sex Health"},{"issue":"5","key":"10.1016\/j.vaccine.2014.08.048_bib0060","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ypmed.2009.02.011","article-title":"Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained","volume":"48","author":"Puig-Junoy","year":"2009","journal-title":"Prev Med"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0065","series-title":"28th International human papillomavirus conference & clinical and public health workshops","article-title":"Impact of HPV vaccination on cost-effectiveness of existing screening programs: example from New Zealand","author":"Canfell","year":"2012"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2014.08.048_bib0070","doi-asserted-by":"crossref","first-page":"F157","DOI":"10.1016\/j.vaccine.2012.06.091","article-title":"Modeling preventative strategies against human papillomavirus-related disease in developed countries","volume":"30","author":"Canfell","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2014.08.048_bib0075","doi-asserted-by":"crossref","first-page":"445","DOI":"10.2165\/00019053-200017050-00004","article-title":"Modelling in health economic evaluation. What is its place? What is its value?","volume":"17","author":"Brennan","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.048_bib0080","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00019053-200624040-00006","article-title":"Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment","volume":"24","author":"Philips","year":"2006","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.vaccine.2014.08.048_bib0085","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2165\/00019053-200017050-00005","article-title":"Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application","volume":"17","author":"Sculpher","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"10.1016\/j.vaccine.2014.08.048_bib0090","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.clinthera.2010.06.017","article-title":"Proceedings of the modeling evidence in HPV pre-conference workshop in Malm\u00f6: Sweden, May 9\u201310, 2009","volume":"32","author":"Craig","year":"2010","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2014.08.048_bib0095","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00019053-200017050-00003","article-title":"Decision analytic modelling in the economic evaluation of health, technologies. A consensus statement. Consensus Conference on Guidelines on Economic Modelling in Health Technology Assessment","volume":"17","year":"2000","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.vaccine.2014.08.048_bib0100","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/j.1524-4733.2010.00698.x","article-title":"Empirically evaluating decision-analytic models","volume":"13","author":"Goldhaber-Fiebert","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0105","series-title":"IARC Working Group on the evaluation of cancer preventative strategies. IARC handbooks of cancer prevention","first-page":"201","article-title":"Effectiveness of screening in populations","volume":"vol. 10","author":"IARC Working Group on the Evaluation of Cancer","year":"2005"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0110","series-title":"Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities","author":"National Health and Medical Research Council (NHMRC)","year":"2005"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0115","series-title":"Colposcopy and programme management: guidelines for the NHS cervical screening programme","author":"NHS Cancer Screening Programmes","year":"2004"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0120","series-title":"Guidelines for cervical screening in New Zealand: incorporating the management of women with abnormal cervical smears","author":"National Screening Unit","year":"2008"},{"issue":"1","key":"10.1016\/j.vaccine.2014.08.048_bib0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.bjc.6600974","article-title":"Benefit of cervical screening at different ages: evidence from the UK audit of screening histories","volume":"89","author":"Sasieni","year":"2003","journal-title":"Br J Cancer"},{"issue":"1305","key":"10.1016\/j.vaccine.2014.08.048_bib0135","first-page":"15","article-title":"Monitoring the performance of New Zealand's National Cervical Screening Programme through data linkage","volume":"122","author":"Lewis","year":"2009","journal-title":"N Z Med J"},{"issue":"10","key":"10.1016\/j.vaccine.2014.08.048_bib0140","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jnci\/djp089","article-title":"Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study","volume":"101","author":"Melnikow","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0145","unstructured":"IARC, European Cancer Observatory, 2007 [cited 2011 March 1]. Available from: http:\/\/eu-cancer.iarc.fr\/."},{"issue":"3","key":"10.1016\/j.vaccine.2014.08.048_bib0150","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1071\/SH07043","article-title":"A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program","volume":"4","author":"Kulasingam","year":"2007","journal-title":"Sex Health"},{"issue":"29","key":"10.1016\/j.vaccine.2014.08.048_bib0155","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1016\/j.vaccine.2007.04.086","article-title":"The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada","volume":"25","author":"Brisson","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0160","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1186\/1471-2458-9-401","article-title":"A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females","volume":"9","author":"Anonychuk","year":"2009","journal-title":"BMC Public Health"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2014.08.048_bib0165","doi-asserted-by":"crossref","first-page":"F16","DOI":"10.1016\/j.vaccine.2008.02.040","article-title":"Comparison of detailed and succinct cohort modelling approaches in a multi-regional evaluation of cervical cancer vaccination","volume":"26","author":"Debicki","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.048_bib0170","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1017\/S0266462310000085","article-title":"Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark","volume":"26","author":"Olsen","year":"2010","journal-title":"Int J Technol Assess Health Care"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2014.08.048_bib0175","doi-asserted-by":"crossref","first-page":"F29","DOI":"10.1016\/j.vaccine.2008.05.069","article-title":"Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios","volume":"26","author":"Suarez","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.048_bib0180","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3111\/13696998.2010.485951","article-title":"Cost effectiveness of prophylactic HPV 16\/18 vaccination in Finland: results from a modelling exercise","volume":"13","author":"Torvinen","year":"2010","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.vaccine.2014.08.048_bib0185","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1017\/S0266462307080026","article-title":"Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France","volume":"24","author":"Bergeron","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.048_bib0190","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00038-010-0216-6","article-title":"A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer","volume":"56","author":"Demarteau","year":"2011","journal-title":"Int J Public Health"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.048_bib0195","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3111\/13696998.2010.490481","article-title":"Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer","volume":"13","author":"Demarteau","year":"2010","journal-title":"J Med Econ"},{"issue":"1","key":"10.1016\/j.vaccine.2014.08.048_bib0200","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3111\/13696990903546013","article-title":"The cost effectiveness of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) in Hungary","volume":"13","author":"Dasbach","year":"2010","journal-title":"J Med Econ"},{"issue":"12","key":"10.1016\/j.vaccine.2014.08.048_bib0205","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.3109\/00016340903322750","article-title":"Cost-effectiveness of human papilloma virus vaccination in Iceland","volume":"88","author":"Oddsson","year":"2009","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"44","key":"10.1016\/j.vaccine.2014.08.048_bib0210","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1016\/j.vaccine.2008.07.098","article-title":"Cost-effectiveness of human papillomavirus vaccine in reducing the risk of cervical cancer in Ireland due to HPV types 16 and 18 using a transmission dynamic model","volume":"26","author":"Usher","year":"2008","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.048_bib0215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/eurpub\/ckp141","article-title":"A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme","volume":"20","author":"Dee","year":"2010","journal-title":"Eur J Public Health"},{"issue":"19","key":"10.1016\/j.vaccine.2014.08.048_bib0220","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1016\/j.vaccine.2010.02.080","article-title":"The health technology assessment of bivalent HPV vaccine Cervarix in Italy","volume":"28","author":"La Torre","year":"2010","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.048_bib0225","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2008.09.031","article-title":"Health and economic impact associated with a quadrivalent HPV vaccine in Italy","volume":"112","author":"Mennini","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"15","key":"10.1016\/j.vaccine.2014.08.048_bib0230","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/jnci\/djp183","article-title":"Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands","volume":"101","author":"de Kok","year":"2009","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.048_bib0235","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ijc.24000","article-title":"HPV16\/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness","volume":"124","author":"Coupe","year":"2009","journal-title":"Int J Cancer"},{"issue":"35","key":"10.1016\/j.vaccine.2014.08.048_bib0240","doi-asserted-by":"crossref","first-page":"4776","DOI":"10.1016\/j.vaccine.2009.05.085","article-title":"Cost-effectiveness of prophylactic vaccination against human papillomavirus 16\/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands","volume":"27","author":"Rogoza","year":"2009","journal-title":"Vaccine"},{"issue":"33","key":"10.1016\/j.vaccine.2014.08.048_bib0245","doi-asserted-by":"crossref","first-page":"6245","DOI":"10.1016\/j.vaccine.2007.05.061","article-title":"Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands","volume":"25","author":"Boot","year":"2007","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2014.08.048_bib0250","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1586\/14737167.8.5.491","article-title":"Assessment of the cost-effectiveness of a quadrivalent HPV vaccine in Norway using a dynamic transmission model","volume":"8","author":"Dasbach","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.048_bib0255","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/eurpub\/ckp208","article-title":"Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia","volume":"20","author":"Obradovic","year":"2010","journal-title":"Eur J Public Health"},{"issue":"6","key":"10.1016\/j.vaccine.2014.08.048_bib0260","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/eurpub\/ckn064","article-title":"Long-term clinical impact of introducing a human papillomavirus 16\/18 AS04 adjuvant cervical cancer vaccine in Spain","volume":"18","author":"Gauthier","year":"2008","journal-title":"Eur J Public Health"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0265","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1478-7547-6-4","article-title":"Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis","volume":"6","author":"Kulasingam","year":"2008","journal-title":"Cost Eff Resour Alloc"},{"issue":"24","key":"10.1016\/j.vaccine.2014.08.048_bib0270","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1016\/j.vaccine.2009.09.125","article-title":"Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom","volume":"28","author":"Choi","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0275","doi-asserted-by":"crossref","first-page":"a769","DOI":"10.1136\/bmj.a769","article-title":"Economic evaluation of human papillomavirus vaccination in the United Kingdom","volume":"337","author":"Jit","year":"2008","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.vaccine.2014.08.048_bib0280","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/sj.bjc.6603501","article-title":"Estimating the long-term impact of a prophylactic human papillomavirus 16\/18 vaccine on the burden of cervical cancer in the UK","volume":"96","author":"Kohli","year":"2007","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.vaccine.2014.08.048_bib0285","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1093\/aje\/kwk059","article-title":"Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty","volume":"165","author":"Van de Velde","year":"2007","journal-title":"Am J Epidemiol"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.048_bib0290","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ijc.20846","article-title":"Natural history and screening model for high-risk human papillomavirus infection: neoplasia and cervical cancer in the Netherlands","volume":"115","author":"Berkhof","year":"2005","journal-title":"Int J Cancer"},{"issue":"12","key":"10.1016\/j.vaccine.2014.08.048_bib0295","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/oxfordjournals.aje.a010166","article-title":"Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis","volume":"151","author":"Myers","year":"2000","journal-title":"Am J Epidemiol"},{"issue":"8","key":"10.1016\/j.vaccine.2014.08.048_bib0300","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1093\/jnci\/djh104","article-title":"Projected clinical benefits and cost-effectiveness of a human papillomavirus 16\/18 vaccine","volume":"96","author":"Goldie","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0305","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/epirev\/mxj006","article-title":"Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease","volume":"28","author":"Dasbach","year":"2006","journal-title":"Epidemiol Rev"},{"issue":"1","key":"10.1016\/j.vaccine.2014.08.048_bib0310","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3201\/eid1301.060438","article-title":"Model for assessing human papillomavirus vaccination strategies","volume":"13","author":"Elbasha","year":"2007","journal-title":"Emerg Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2014.08.048_bib0315","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1007\/s11538-008-9338-x","article-title":"A multi-type HPV transmission model","volume":"70","author":"Elbasha","year":"2008","journal-title":"Bull Math Biol"},{"issue":"8","key":"10.1016\/j.vaccine.2014.08.048_bib0320","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1471-0528.2008.01743.x","article-title":"The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6\/11\/16\/18) in the UK","volume":"115","author":"Dasbach","year":"2008","journal-title":"BJOG"},{"issue":"3","key":"10.1016\/j.vaccine.2014.08.048_bib0325","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/imammb\/11.3.161","article-title":"Balancing sexual partnerships in an age and activity stratified model of HIV transmission in heterosexual populations","volume":"11","author":"Garnett","year":"1994","journal-title":"IMA J Math Appl Med Biol"},{"issue":"Suppl. 5","key":"10.1016\/j.vaccine.2014.08.048_bib0330","doi-asserted-by":"crossref","first-page":"F46","DOI":"10.1016\/j.vaccine.2008.02.039","article-title":"Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis","volume":"26","author":"Rogoza","year":"2008","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2014.08.048_bib0335","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-132-10-200005160-00009","article-title":"Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review","volume":"132","author":"Nanda","year":"2000","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.vaccine.2014.08.048_bib0340","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/oxfordjournals.aje.a117485","article-title":"Meta-analysis of Pap test accuracy","volume":"141","author":"Fahey","year":"1995","journal-title":"Am J Epidemiol"},{"issue":"8964","key":"10.1016\/j.vaccine.2014.08.048_bib0345","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/S0140-6736(95)91086-7","article-title":"Human papillomavirus testing in primary cervical screening","volume":"345","author":"Cuzick","year":"1995","journal-title":"Lancet"},{"issue":"9601","key":"10.1016\/j.vaccine.2014.08.048_bib0350","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1016\/S0140-6736(07)61450-0","article-title":"Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial","volume":"370","author":"Bulkmans","year":"2007","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.vaccine.2014.08.048_bib0355","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1002\/ijc.21513","article-title":"Evaluation of cervical screening strategies with adjunct high-risk human papillomavirus testing for women with borderline or mild dyskaryosis","volume":"118","author":"Berkhof","year":"2006","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.vaccine.2014.08.048_bib0360","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0029-7844(98)00006-4","article-title":"Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis","volume":"91","author":"Mitchell","year":"1998","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.vaccine.2014.08.048_bib0365","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00006254-199802000-00021","article-title":"Positive predictive rate of colposcopic examination of the cervix uteri: an overview of literature","volume":"53","author":"Hopman","year":"1998","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0370","series-title":"IARC handbook of cancer prevention: cervical screening","first-page":"59","article-title":"Screening tests","author":"International Agency for Research on Cancer (IARC)","year":"2005"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0375","series-title":"Automation-assisted and liquid based cytology for cervical cancer screening. MSAC application 1122, MSAC","author":"MSAC","year":"2009"},{"issue":"6","key":"10.1016\/j.vaccine.2014.08.048_bib0380","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1177\/030089160208800609","article-title":"Recurrence after treatment by loop electrosurgical excision procedure (LEEP) of high-grade cervical intraepithelial neoplasia","volume":"88","author":"Cecchini","year":"2002","journal-title":"Tumori"},{"issue":"10","key":"10.1016\/j.vaccine.2014.08.048_bib0385","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1002\/ijc.24634","article-title":"EUROGIN 2008 roadmap on cervical cancer prevention","volume":"125","author":"Franceschi","year":"2009","journal-title":"Int J Cancer"},{"key":"10.1016\/j.vaccine.2014.08.048_bib0390","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1741-7015-11-80","article-title":"Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement","volume":"11","author":"Husereau","year":"2013","journal-title":"BMC Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14011712?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14011712?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T10:06:09Z","timestamp":1565777169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14011712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0264410X14011712"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.08.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a quality framework for models of cervical screening and its application to evaluations of the cost-effectiveness of HPV vaccination in developed countries","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.08.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}